|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cloning and expression of core gene cDNA of Chinese hepatitis C virus in cosmid pTM3显示文摘AIM To clone core gene cDNA of Chinesehepatitis C virus(HCV)into eukaryoticexpression vector cosmid pTM3 and to expressHCV core antigen in HepG2 cells.METHODS Core gene cDNA of HCV wasintroduced into eukaryotic expression vectorcosmid pTM3.Using vaccinia virus/bacteriophage T7 hybrid expression system,HepG2 cells were transfected with therecombinant plasmid pTM3-Q534 by lipofectin.RESULTS From the transfected bacteriaTop10F’,2 pTM3-Q534 clones containing therecombinant plasmid were identified fromrandomly selected 10 ampicillin-resistantcolonies.By reverse transcription PCR andindirect immunofluorescence technique,HCVRNA and core protein was identified in HepG2cells transfected with the recombinant plasmid.CONCLUSION The construction of arecombinant plasmid and the expression of coregene cDNA of HCV in HepG2 was successful. | Jiang RL Lu QS Luo KX | 2000 | World Journal of Gastroenterology2000，6，2： | 12 |
| 2 | Transfusion transmitted virus infection in general populations and patients with various liver diseases in south China显示文摘INTRODUCTIONAlthough several specific detecting methods hadbeen applied to determine the hepatitis virus,therewas a lot of cryptogenic hepatitis without anyknown hepatitis infectious marker.Theprevalence of hepatitis G virus (HGV) (also knownas GB-C virus) infection has been reported to be 5%-13% in patients with non-A-E hepatitis andcirrhosis,however,there is little evidencesuggesting that HGV causes hepatitis in human. | Chen YP Liang WF Zhang L He HT Luo KX | 2000 | World Journal of Gastroenterology2000，6，5： | 7 |
| 3 | Impact of virus genotype on interferon treatment of patients with chronic hepatitis C: a multicenter controlled study显示文摘BACKGROUND: Some factors have been reported to besassociated with a greater likelihood of sustained viral re-sponse ( SVR) in the interferon (IFN) treatment of chronichepatitis C. The factors include HCV genotype, HCVRNA level in serum, state of liver disease, baseline bodyweight, age, sex, and race. The aim of this trial was to in-vestigate the influence of HCV genotype on the IFN treat-ment of patients with chronic hepatitis C.METHODS: The genotypes of HCV virus were determinedin the patients with chronic hepatitis C from several hospi-tals of China enrolled into the randomized, opened andcontrolled trial of Peg-IFN alpha-2a (pegasys) treatment,controlled with IFN-α-2a (roferon-A). The serum ALTlevels and HCV RNA concentrations of the patients weredetected before and at the end of treatment and during thefollow-up. The influence of HCV genotype on the IFNtreatment of patients with chronic hepatitis C was analyzedin intention-to-treat (ITT) population.RESULTS: The HCV genotypes of 202 patients were deter-mined. Of these patients, 158(78.22%) were infected withgenotype 1 HCV and 44(21.78%) with genotype non-1.The viral response at the end of treatment (ETVR) andsustained viral response (SVR) rates were 53.80% and25.32% respectively in patients with genotype 1 HCV, butthey were 61.36% and 43.18% in patients with genotypenon-1. The difference of SVR between patients with geno-type 1 HCV and those with genotype non-1 was significant(P =0.021). After being grouped by the used drugs, theETVR rates of patients infected with genotype 1 and non-1HCV were 76.83% and 80.95% in the patients treated withpegasys (P =0.686); but their SVR rates were 35.37% and66.67% (P =0. 01). The viral relapse rate of genotype 1HCV (55.56%) was significantly higher than that of geno-type non-1 HCV (23.53%) (P=0.02). In roferon-A group,the ETVR and SVR rates of patients with genotype 1 HCVwere 28.95% and 14.47% respectively, which were lowerbut not more significant than those of patients with geno-type non-1 HCV (43.48% and 21.74%). Moreover, the vi-ral relapse rate of genotype 1 HCV (72.73%) was higherbut not more significant than that of genotype non-1 HCV(50.00%) (P=0.21).CONCLUSION: HCV genotype could affect the efficacies,mainly sustained responses, of IFN treatment in patientswith chronic hepatitis C, and the effects of IFN are relatedto drugs and therapeutic course. | Yao Xie, Dao-Zhen Xu, Zhi-Meng Lu, Kang-Xian Luo, Ji-Dong Jia, Yu-Ming Wang,Gui-Zhen Zhao, Shu-Lin Zhang and Da-Zhi Zhang Department of Infeetious Diseases , Beijing Ditan Hos-pital, Beijing 100011 , China Department of Infec-tious Diseases, Ruijin Hospital, Shanghai 200025, China De-partment of Infectious Diseases, Naifang Hospital, First Military Medical U-niversity, Guangzhou 510515, China (Luo KX) Center of Liver Disease,Beijing Friendship Hospital, Beijing 100050, China (Jia J D ) Institute ofInfectious Disease, Southwest Hospital, Third Military Medical University,Chongqing 410032, China Department of Infectious Disea-ses, Second Hospital, China Medical University, Shenyang 110004, China Department of Infectious Diseases, First Hospital, Xi’ an Jiao-tong University, Xi’ an 710061 , China ) Liver Disease Centerof Chongqing, Second Hospital, Chongqing Medical University,Chongqing 410010, China | 2004 | Hepatobiliary & Pancreatic Diseases International2004，3，3： | 2 |
| 4 | Peginterferon alfa-2a.lamivudine,and the combination for HBeAg-positive chronic hepatitis B显示文摘 | Lau GK Piratvisuth T Luo KX | | 0，，： | 2 |
| 5 | Ski and SnoN:negative regulators of TGF-β signaling 显示文摘 | Luo KX | 2004 | Current Opinion in Genetics & Development2004，14，1： | 1 |
| 6 | Intrahepatic transfusion-transmitted virus detected by in situ hybridization in patients with liver diseases 显示文摘 | Jiang XJ Luo KX He HT | 2000 | J Virol Hepat2000，7，1： | 1 |
| 7 | An outbrak of enterically transcnitted non-A,nonE viral hepatitis显示文摘 | Luo KX Zhang L | 1999 | J Viral Hepat1999，6，： | 1 |
| 8 | Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B显示文摘 | Lau GK Piratvisuth T Luo KX | 2005 | N Engl J Med2005，352，26： | 1 |
| 9 | Peginterferon ct-2a as monotherapy and in combination with HBeAg positivechronic hepatitis B显示文摘 | Laug KK Piratvisut HT Luo KX | 2004 | Hepatology2004，38，1： | 1 |
| 10 | HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a forHBeAg-positive chronic hepatitis B 显示文摘 | Fried MW Piratvisuth T Lau GK Marcellin P Chow WC Cooksley G Luo KX Paik SW Liaw YF Button P Popescu M | 2008 | Hepatology2008，47，2： | 1 |
| 11 | Peginterferon Alfa-2a,lamivudine,and the combination for HBeAg-positive chronic hepatitis B显示文摘 | Lau GK Piratvisuth T Luo KX | 2005 | N Engl J Med2005，352，： | 1 |
| 12 | Peginterferon Alfa- 2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B显示文摘 | Lau GK Piratvisuth T Luo KX | 2005 | N Engl J Med2005，352，26： | 1 |
| 13 | In situ investigation of Fas/FasL expression in chronic hepatitis B infection and related liver diseases显示文摘 | Luo KX Zhu YF Zhang LX | 1997 | J Viral Hepat1997，4，： | 1 |
| 14 | Peginterferon alfa - 2a, lamivudine, and the combination for HBeAg -positive chro- nic hepatitis B显示文摘 | LAU GK PIRATVISUTH T LUO KX | 2005 | N Engl J Med2005，352，26： | 1 |
| 15 | Peginteron alfa-2a Lamivudine and the combination for HBeAg-positive chronic hepatitis B显示文摘 | Lau GK Piratvisuth T Luo KX | 2005 | N Engl J Med2005，352，： | 1 |
| 16 | Peginterferon alfa-2a,lamivudine,and the combination for HBeAg-positive chronic hepatitis B显示文摘 | Lau GK Piratvisuth T Luo KX | 2005 | N Engl J MecL2005，352，： | 1 |
| 17 | Peginterferon Alfa- 2 &,L~mivudine,&nd the Combin&tion for HBeAg Positive Chronic Hep&titis B显示文摘 | L&u GKK Piratvisuth T Luo KX et &l | 2005 | N Engl J Med2005，352，： | 1 |
| 18 | Is non--responsiveness to hepatitis B vaccine due to latent hepatitis B virus infection?显示文摘 | Wang LP Jun N | 1992 | The journal of infections disease1992，165，4： | 1 |
| 19 | Lactosamination of liposomes and hepatotropic targeting research显示文摘INTRODUCTIONSite-specific delivery of therapeutic drags to their targetcells is a major scientific challenge for the pharmaceuticalsciences.It offers a number of advantages overconventional drag administration.With drag targeting,high local concentrations of the drag can be achieved,thuscircumventing many unwanted side effects.Various | Chen YP Zhang L Lu QS Feng XR Luo KX | 2000 | World Journal of Gastroenterology2000，6，4： | 1 |
| 20 | Peginterferon Alfa-2a, larnivudine, and the combination for HBeAg-positive chronic hepatitisB显示文摘 | Lau GK Piratvisuth T Luo KX | 2005 | NEnglJ Med2005，352，26： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员